Reference
Nguyen, K., Zhang, D., Roberts, E., Yun, S., McGraw, K., Abraham, I., Song, D., Braswell, D., Qin, D., Sallman, D., Lancet, J., List, A., Moscinski, L., Padron, E., & Zhang, D. (2020). Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated versus acute myeloid leukemia with myelodysplasia-related changes with mutated . 61(6). https://doi.org/10.1080/10428194.2020.1723016
Abstract
Studies comparing the prognostic role of mutations () in acute myeloid leukemia (AML) and acute myeloid leukemia-with myelodysplasia-related changes (AML-MRC) are limited. Our study examines the genetic profile of 118 AML patients including 57 AML with and 61 AML-MRC with and 100 AML, NOS patients with wild type (). Results revealed that AML-MRC patients with had shorter median overall survival (OS) (11 ± 3.3 months) when compared to AML with (19 ± 7.1 months) and AML, NOS with (not reached) ( = .001). The most common concurrent mutations observed in AML-MRC with patients were , , , and while in AML with patients were , , , , and . and mutations appeared to adversely affect OS in AML-MRC, but not in AML with . Concurrent mutations, in contrast had negative impact on OS in AML with , but not in AML-MRC with .